Grail is a healthcare company focused on early cancer detection with a pan-cancer blood test that analyzes circulating tumor DNA (ctDNA) and other nucleic acids. Using advanced sequencing technology, it aims to detect cancers at early, treatable stages. Founded in 2016 by Alex Aravanis and Jeff Huber, Grail is based in Menlo Park, California, and has conducted large-scale clinical trials to validate its test.